Disease Progression on PROs in Patients With aNSCLC With PD-L1 ?50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1 için istatistikler

Toplam ziyaret

views
Disease Progression on PROs in Patients With aNSCLC With PD-L1 ?50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1 0

Aylık toplam ziyaret

views
Ekim 2024 0
Kasım 2024 0
Aralık 2024 0
Ocak 2025 0
Şubat 2025 0
Mart 2025 0
Nisan 2025 0